ImmuneMed's hzVSF-v13, COVID-19 clinical trials accelerate development of the treatment


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ ImmuneMed's hzVSF-v13, COVID-19 clinical trials accelerate development of the treatment
The broad-spectrum antiviral therapeutic, 'hzVSF-v13(humanized Virus Suppressing Factor)' being developed by ImmuneMed, is on track to progress as a treatment for the COVID-19 pneumonia patients.

The broad-spectrum antiviral therapeutic, 'hzVSF-v13(humanized Virus Suppressing Factor)' being developed by ImmuneMed, is on track to progress as a treatment for the COVID-19 pneumonia patients.

Currently, it is smoothly progressing with the approval for Phase 2 clinical trials in four countries, and it is expected to see the results sequentially starting as early as the third quarter of 2021.

ImmuneMed received approval from the Ministry of Food and Drug Safety(MFDS) for the compassionate use of hzVSF-v13 as treatment of severe COVID-19 and then identified its potential by targeting 7 patients in 4 hospitals. In particular, two COVID-19 pneumonia patients administered at Seoul National University Hospital became virus-free within 10 days by administering hzVSF-v13 twice or three times. They were completely cured of their pneumonia due to reduced clinical symptoms and decreased CRP, the most sensitive marker for acute-phase inflammation, and inflammatory cytokines including IL-6, TNF-a, and MCP-1. The researcher of Seoul National University Hospital published the results as entitled "Compassionate use of hzVSF-v13 in two patients with severe COVID-19" in the Journal of Medical Virology in May 2020.

Prior to this, the safety of hzVSF-v13 has confirmed in Phase 1 clinical study in Korea and another Phase 1 clinical trial is underway in Australia. ImmuneMed carried forward with the Phase 2 clinical trial after analyzing the results of the Phase 1 study and compassionate use of hzVSF-v13 against COVID-19. The Phase 2 clinical study was approved last October, starting from Russia and then Indonesia, Korea, and Italy, sequentially.

Although there will be differences in clinical studies among countries, the company plans to finalize all the Phase 2 clinical studies by sometime next year. Also, based on the Pre-IND meeting feedback, ImmuneMed is preparing an IND application to the FDA and is aiming to initiate the Phase 2 clinical study within the first half of 2021.

hzVSF-v13 is a new drug candidate that ImmuneMed is developing as a treatment for various viral diseases, and the company has been developing treatments for chronic hepatitis B and severe influenza pneumonia. Due to the COVID-19 pandemic, it is also developing COVID-19 treatments based on the research data on coronavirus disease and antiviral efficacy data with SARS-CoV-2. ImmuneMed is also planning to start a Phase 2 clinical study within the first quarter of 2021 regarding chronic hepatitis B which is another indication of hzVSF-v13.

ImmuneMed is a biotech company established in 2000 that develops treatment of viral diseases using hzVSF-v13 and runs a rapid diagnostic kit business for infectious diseases such as COVID-19.

Tags : #ImmuneMed #broad-spectrum #antiviraltherapeutic #hzVSF-v13 #humanizedVirusSuppressingFactor #TreatmentofCovid #Covid-19Infection #COVID-19pneumoniapatients #ClinicalTrials #FightAgainstCovidInfection

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Puja Curtains go up with KHUTI PUJA at Hazra Park DurgotsabJune 14, 2025
Medanta-Moolchand Heart Centre Expands Advanced Cardiac Care in South DelhiJune 14, 2025
Celebrating Every Gentle Touch — Himalaya BabyCare Unveils #GentleAsDad CampaignJune 14, 2025
Will we rise to #endAIDS challenge or stumble withering away the gains in HIV response?June 14, 2025
Wearable Biosensors in Diabetes Monitoring: A Patient Centric ApproachJune 14, 2025
Crack the Longevity Code: Why Flavonoid Variety Could Be the New Fountain of YouthJune 14, 2025
Why You Might Be Healthier Without Losing a Single KiloJune 14, 2025
The Great Unfollow: Why Patients Are Distrusting Influencer DoctorsJune 14, 2025
The Great Unfollow: Why Patients Are Distrusting Influencer DoctorsJune 14, 2025
Sleep Clinics Boom in Tier 2 Cities: What’s Fueling the Demand?June 14, 2025
Flight to Nowhere: The Air India Crash That Shook Ahmedabad and Raised Global Safety AlarmsJune 13, 2025
She Went for Pain Relief, Came Back With a Torn Artery: A Chiropractic Horror StoryJune 13, 2025
Biology vs Burnout: What Night Shifts Are Really Doing to Your Brain and BodyJune 13, 2025
Renowned Gynaecologist Joins Manipal Hospital Gurugram to Strengthen Women’s HealthJune 13, 2025
Aster CMI Hospital Saves Young Woman from Limb Loss in Rare Vascular SurgeryJune 13, 2025
QNET Unveils Father’s Day Gifts to Honour the Everyday Hero in Your LifeJune 13, 2025
Manipal Hospital Ghaziabad becomes first in the city to perform REZUM to treat prostate enlargementJune 13, 2025
Gen Z Doctors: Rethinking the White Coat Culture in IndiaJune 13, 2025
How Menopause Is Finally Becoming a Mainstream Medical ConversationJune 13, 2025
Thinner Bodies, Heavier Minds: When Diets Damage Mental HealthJune 13, 2025